The global dermatology prescription market is expected to continue growing at a rapid pace.
In our Therapeutic Dermatology business we provide dermatologists and other healthcare professionals with prescription treatments that offer patients relief from the burden of moderate to severe skin diseases. We have a wide-ranging portfolio and our innovation is focused on developing new therapies in more disease areas with unmet medical needs.
One of our key priorities is to advance the development of the investigational therapy nemolizumab in patients with atopic dermatitis and prurigo nodularis for which we are completing Phase 3 clinical studies.
With continuous innovation as a key driver for our sustainable growth, our R&D teams work relentlessly to help ensure we meet individual consumer and patient needs with superior outcomes. We have developed a best-in-class pipeline and a track record of first-to-market innovation.
We aim to become the leader in dermatology, prioritizing biotechnologies for injectable and oral products. A top priority for us is the development of the investigational therapy nemolizumab for atopic dermatitis, prurigo nodularis and chronic kidney disease-associated pruritus. We are actively investigating other indications within and beyond dermatology.